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Abstract
After radical treatment of head and neck cancer about 20–50% of patients are diagnosed 
with the locoregional recurrence during first two years. The main treatment for recurrent 
disease is salvage surgery, but in most cases, surgery is not feasible due to the high risk of 
complications and morbidity, and only 20% of patients are suitable for surgical salvage. 
Reirradiation is an effective treatment method with acceptable toxicity, but this treat-
ment method is limited to normal tissue tolerance to a total dose. When chemotherapy is 
administered for recurrence, the response rate is up to 40%, so with the advancement of 
technical measures, after introduction of intensity‐modulated radiotherapy, fractionated 
stereotactic body radiation therapy, high‐dose‐rate brachytherapy, proton beam reirra-
diation, a reirradiation is increasingly more often used for head and neck cancer relapse 
treatment. In this chapter, we will discuss about reirradiation with curative intent using 
new different radiation techniques (intensity‐modulated radiotherapy (IMRT), stereotac-
tic body radiation therapy (SBRT), high‐dose‐rate brachytherapy (HDR‐BRT) and proton 
beam reirradiation (PBRT) for previously irradiated head and neck cancer and present 
recommendations for retreatment of head and neck cancer relapse using reirradiation 
alone or with systemic chemotherapy/biologic therapy.
Keywords: reirradiation, head and neck cancer, brachytherapy, proton beam therapy, 
stereotactic body radiation
1. Introduction
Despite the sophisticated methods of cancer diagnosis, more than 50% of cases are still diag-
nosed when the disease has reached III/IV stage. After radical treatment of head and neck can-
cer, about 20–50% of patients are diagnosed with the locoregional recurrence during first two 
years [1–3]. The main treatment for recurrent disease is salvage surgery, but in most cases, 
surgery is not feasible due to the high risk of complications and morbidity, and only 15–30% 
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of patients are suitable for surgical salvage [4–8], and 5‐year overall survival is 16–36% [9–14]. 
When chemotherapy is administered for recurrence, the response rate is up to 35–40%, and 
median overall survival is about 10% [15–17]. The results of retrospective studies presented in 
literature, using reirradiation by three‐dimensional radiotherapy (3D‐RT) for head and neck 
cancer recurrence, according to a 2‐year overall survival and toxicity, are poor: overall sur-
vival reached 15.2–40%, the rate of severe late toxicities (grade 3 and 4) reached 1.4–47%, the 
rate of degree 5 (lethal) complications reached 7.6% [18–21]. However, with the advancement 
of technical measures, after introduction of intensity‐modulated radiotherapy (IMRT), frac-
tionated stereotactic body radiation therapy (F‐SBRT), high‐dose‐rate brachytherapy (HDR‐
BRT), proton beam reirradiation (PBRT), a reirradiation is increasingly more often used for 
head and neck cancer relapse treatment [6, 18, 22–24].
In this chapter, we will discuss about reirradiation with curative intent using new different 
radiation techniques (IMRT, SBRT, HDR‐BRT and PBRT) for previously irradiated head and 
neck cancer and present recommendations for retreatment of head and neck cancer relapse 
using reirradiation alone or with systemic chemotherapy/biologic therapy.
2. Reirradiation techniques and outcomes
2.1. Intensity‐modulated radiotherapy and stereotactic body radiotherapy reirradiation
When comparing IMRT and F‐SBRT against 3D‐RT technique, it is possible to apply a larger 
radiation total dose during IMRT and F‐SBRT, better protect adjacent tissues, while also 
achieving a better dose homogeneity. Lee et al. published results of 105 patients treated for 
head and neck cancer relapse using external beam radiation therapy [25]. Study included 
74 (70%) patients treated with IMRT, 16 (15%) patients received conformal 3D radiation 
therapy and 15 (15%) patients received 2D radiation therapy. Prior to reirradiation, surgi-
cal treatment was performed on 36 (34%) patients, chemotherapy (mostly platinum‐based) 
was administered to 75 (71%) patients, including 45 (43%) cases combined with radiation 
therapy. The median reirradiation dose was 59.4 Gy (range 30–70 Gy), median cumulative 
dose was 121.4 Gy (range 88–137 Gy). The 1‐year and 2‐year overall survival was 56% and 
37%, respectively; locoregional control was 48% and 42%, respectively. The frequencies of 
early and late grade 3 and 4 toxicities were 23% and 15% (early and late, respectively). Sulman 
et al. conducted a retrospective analysis of 74 patients who were treated for head and neck 
cancer relapse and secondary cancer by applying IMRT to the previously irradiated area [24]. 
Before the reirradiation, 20 (27%) patients underwent surgery, 36 (48.6%) patients received 
chemotherapy: 23 patients received concurrent chemotherapy, four (11.1%) patients received 
induction chemotherapy, one (2.8%) patient received adjuvant chemotherapy, seven (19.4%) 
patients received induction and concurrent chemotherapy and one patient received concur-
rent and adjuvant chemotherapy. Platinum‐based chemotherapy was administered to nine 
(25%) patients, 23 (64%) patients received a combined platinum‐ and taxane‐based chemo-
therapy, three (8.3%) patients received platinum‐ and 5‐fluorouracil‐based treatment and 
one patient was administered a medication based on platinum with taxanes and lonafarnib 
(farnesyltransferase inhibitor). Median survival was 27.6 months; 2‐year overall survival and 
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locoregional control were 58% and 64%, respectively. Severe late toxicity (grade 3 and 4) was 
observed in 15 (20%) patients; one patient died (grade 5 toxic reaction). Duprez et al. pub-
lished medical results based on 84 patients treated for recurrent or secondary head and neck 
cancer using IMRT [26]. Concurrent platinum‐based chemotherapy was administered to 17 
(20%) patients, 19 patients underwent surgical treatment and IMRT. Median dose delivered 
by IMRT was 69 Gy, median cumulative dose was 130 Gy (range 71–138 Gy). Median survival 
was 13.4 months; 1‐year, 2‐year and 5‐year overall survival was 54%, 35%, and 20%, respec-
tively; progression‐free survival was 58%, 42%, and 29%, respectively. Severe early toxicity 
occurred in 26 (31%) patients, late toxicity occurred in 52 (62%) patients (grade 3 and 4 in 
11 (13.1%) patients). Late grade 5 reactions occurred in two (2.4%) patients. It was deter-
mined during this study that T4 (p = 0.013), >2 years time interval between primary radiation 
therapy and reirradiation (p = 0.011), and hypopharyngeal cancer (p = 0.013) are statistically 
significant unfavorable factors impacting the overall survival, while the concurrent chemo-
therapy (p = 0.0009) is related to higher frequency of severe complications (grade 3 and 4). 
Chen et al. completed a retrospective study which included 21 patients [27]. All patients were 
diagnosed with recurrent head and neck cancer or secondary tumor, and IMRT was used 
in combination with image‐guided radiation therapy (IGRT). The 1‐year and 2‐year overall 
survival was 65% and 40%, respectively. The authors identified severe acute toxicity frequen-
cies: skin desquamation in 12 (57%) patients, dysphagia in 9 (42%) patients and mucositis 
in 5 (23%) patients. Late reactions: 2 patients were diagnosed with trismus, 1 patient was 
diagnosed with brachial plexopathy and gastrostomy was performed on 12 (57%) patients to 
manage swallowing disorder following the radiation therapy. Similar results were published 
for application of fractional stereotactic body radiation therapy (F‐SBRT). Roh et al. treated 36 
patients (44 areas) diagnosed with head and neck cancer relapse [28]. Median total dose was 
30 Gy (range 18–40 Gy), delivered in 3–5 fractions over 3–5 days prescribed to the 65–85% iso-
dose line. The 1‐year and 2‐year progression‐free survival was 61% and 52.2%, respectively, 
while 1‐year overall survival was 52.1%, 2‐year survival was 30.9%. Early grade 3 reactions 
were diagnosed in 13 patients; late complications (grade 3 and 4) were diagnosed in 3 (8.6%) 
patients. Cengiz et al. used F‐SBRT to treat 46 patients diagnosed with unresectable recurrent 
head and neck cancer [22]. Median total dose was 30 Gy (range 18–35 Gy), delivered mostly in 
five fractions (range 1–5 fractions). Overall 1‐year survival and progression‐free survival was 
47% and 41%, respectively. Frequency of early toxicity was 4.4%: one patient was diagnosed 
with grade 3 dermatitis and grade 1–3 mucositis according to RTOG criteria; grade 5 compli-
cation frequency was 4.4%. Late reactions were diagnosed in six (13.3%) patients: two patients 
were diagnosed with soft tissue necrosis, two patients had osteonecrosis of the mandible and 
two patients were also diagnosed with grade 2 dysphagia. Five (11%) patients died due to 
bleeding from the carotid artery. Siddiqui et al. used stereotactic radiation therapy to treat 
44 patients (55 areas), including 21 patients (29 cases) diagnosed with head and neck cancer 
relapse in primary tumor location or adjacent location [23]. Patients who were diagnosed with 
the relapse in regional neck lymph nodes where not included in this group. Delivered total 
dose was 36 Gy in 6 fractions or 48 Gy in 8 fractions, 2–3 fractions/week or 16–18 Gy single 
fraction. In this group of patients, 1‐year and 2‐year overall survival was 38.1% and 14.3%, 
respectively, local control was 60.6% and 40.4%, respectively. Early grade 3 toxicity was diag-
nosed in one patient; grade 4 complications were diagnosed in three patients.
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In conclusion, it can be stated that the results of external beam reirradiation therapy used to 
treat head and neck cancer relapse, according to the treatment techniques, are: using IMRT, 
2‐year overall survival was 35–58%, locoregional control was 42–64%, 2‐year progression‐
free survival reaches 42%, while the frequency of grade 3 and 4 toxicity was 13.1–20%, fre-
quency of grade 5 radiotherapy reactions up to 2.8% [16, 25, 26, 28]. Results from F‐SBRT 
studies: 2‐year overall survival was 14.3–40%, local control 40.4%, progression‐free survival 
was 52.2%, frequency of late severe complications was 8.6–14%, frequency of grade 5 com-
plications was 2.8–14% [16, 22, 23, 28] (Table 1). During most of these studies, prognostic 
factors have been determined which influence the overall survival, locoregional control and 
progression‐free survival; these factors were: longer time interval between initial radiation 
therapy and reirradiation; chemotherapy or biological therapy, administered in combination 
Author N Treatment Late toxicity grade 3–4 Results
Lee et al. [25] 105 (a) IMRT/(n = 74)
(b) 3D‐RT/(n = 16)
(c) 2D‐RT/(n = 15)
75 pts. received platinum‐based CHT
Median dose 59.4 Gy (30–70 Gy)
15% 1 y OS—56%
2 y OS—37%
1 y LRC—48%
2 y LRC—42%
Sulman et al. [24] 74 (a) Surgery + IMRT/(n = 20)
(b) IMRT + CHT/(n = 36)
(c) IMRT/(n = 48)
Median dose 63 Gy (48.8–70 Gy)
20%
Grade 5—2.8%
2 y OS—58%
2 y LRC—64%
Duprez et al. [26] 84 (a) OP + IMRT/(n = 19)
(b) IMRT + CHT/(n = 17)
(c) IMRT/(n = 48)
Median dose 69 Gy
13.1%
grade 5—2.4%
1 y OS—54%
2 y OS—35%
5 y OS—20%
1 y DFS—58%
2 y DFS—42%
5 y DFS—29%
Chen et al. [27] 21 IMRT, median dose 66 Gy (60–70 Gy) Dysphagia—57%, 
trismus—9.5%, brachial 
plexopathy—4.8%
1 y OS—65%
2 y OS—40%
Roh et al. [28] 36 F‐SBRT, median dose 30 Gy (18–40 Gy) 8.6%
grade 5—2.8%
1 y OS—52.1%
2 y OS—30.9%
1 y LRC—61%
2 y LRC—52.2%
Cengiz et al. [22] 46 F‐SBRT, median dose 30 Gy (18–35 Gy) 13.3%
grade 5—11%
1 y OS—47%
1 y DFS—41%
Siddiqui et al. [23] 21* F‐SBRT/(n = 10):
(a) 36 Gy/6 fx
(b) 48 Gy/8 fx
S‐SBRT/(n = 11):
Single‐fraction 13–18 Gy
Grade 4—14% 1 y OS—38.1%
2 y OS—14.3%
1 y LC—60.6%
2 y LC—40.4%
Notes: 3D‐RT, three‐dimensional conformal radiotherapy; 2D‐RT, two‐dimensional radiotherapy; IMRT, intensity‐
modulated radiotherapy; CHT, chemotherapy; F‐SBRT, fractionated stereotactic body radiation therapy; S‐SBRT, 
radiosurgery; OS, overall survival; LRC, locoregional control; DFS, disease free survival; LC, local control.
* 44 patients participated in study, but results are presented only for 21 patient treated for disease relapse.
Table 1. Summary of published data on IMRT and SBRT for recurrence from head and neck cancer.
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with reirradiation therapy; total dose of reirradiation therapy ≥50 Gy and surgical treatment 
prior to reirradiation therapy. Frequency of severe toxicity (grade 3 and higher) statistically 
significantly depended on the following factors: chemotherapy, administered in combination 
with reirradiation therapy; total dose of reirradiation therapy >60 Gy.
Results of the discussed studies prove that it is possible to achieve good locoregional control 
with acceptable toxic reactions through application of external beam reirradiation therapy. Using 
IMRT method, the number of late radiation reactions was lower compared with 3D‐RT or F‐SBRT.
Recommendations for IMRT (Figure 1):
1. To use repeated IMRT to treat patients with good functional status (Karnofsky 
Performance Score ≥ 60) in combination with chemotherapy or biological therapy after 
surgery, when there are positive resection margins, extracapsular nodal spread, perineu-
ral or lymphovascular infiltration.
2. Minimal time interval between initial radiation therapy and reirradiation 6–12 months.
3. Reirradiation volume: PTV = GTV + 5 mm, total dose ≥50–60 Gy, using conventional frac-
tionation (1.8–2 Gy/fx).
Figure 1. Representative isodose plan for patient undergoing reirradiation: (A) axial and (B) coronal CT slice. The patient 
had recurrent grade 3 adenoid cystic carcinomas of hard palate previously treated to 60 Gy with concurrent cisplatin. A 
local recurrence developed after 15 months, and the patient underwent reirradiation with IMRT to 48 Gy. The clinical 
and planning target volumes are showed in red, the total cumulative dose to brainstem was 51.54 Gy, spinal cord—
42.1 Gy, chiasma—50.4 Gy, n. opticus left—51.2 Gy. No late toxicity was observed after 1 year.
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http://dx.doi.org/10.5772/67060
109
Recommendations for F‐SBRT (Figure 2):
1. To use repeated F‐SBRT to treat patients with good functional status (Karnofsky 
Performance Score ≥ 60) in combination with chemotherapy or biological therapy after 
surgery, when there are positive resection margins, extracapsular nodal spread, perineu-
ral or lymphovascular infiltration.
2. F‐SBRT is not recommended to treat laryngeal and hypopharyngeal site of recurrence 
due to higher frequency of late reactions.
3. Recommended total dose 35–42 Gy in 7 fractions prescribed to the 80–85% isodose line, 
over 2.5 weeks (total dose must not exceed 44 Gy).
2.2. High‐dose‐rate brachytherapy reirradiation
When using brachytherapy, it is possible to directly irradiate the tumor and deliver sufficient 
dose while also reducing the frequency of severe complications, such as trismus or severe 
xerostomia [29, 30]. In published studies, which involved patients with the diagnosis of head 
and neck cancer relapse and who were treated using HDR‐BRT, different treatment regimens 
have been selected.
Hepel et al. published results of study involving 30 patients diagnosed with head and neck 
cancer relapse and treated using 192I‐HDR‐BRT [31]. All patients were treated using external 
beam radiation therapy, delivering mean dose of 59 Gy (range 23–75 Gy), with minimal 1‐year 
follow‐up. Adjuvant chemotherapy was administered to 43% patients, 36% were treated 
using hyperthermia therapy. Using HDR‐BRT, two daily fractions have been prescribed with 
Figure 2. Dosimetric plan (A) used for reirradiation of a patient with recurrent oropharyngeal squamous cell carcinoma; 
dose‐volume histogram is showed in apex (B). The patient underwent radical chemoradiotherapy as primary treatment 
(total dose 68 Gy/34 fx), after local recurrence developed approximately 21 months later, and the patient underwent 
reirradiation with F‐SBRT—35 Gy/7 fx prescribed to the 80% isodose. The total cumulative dose to spinal cord was 
57.8 Gy, mandible—93 Gy, larynx—72.4 Gy, parotid gland left—36 Gy, parotid gland right—72.4 Gy. No late toxicity 
was observed after 1.6 year.
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minimum 6‐hour separation interval. In patients with implant volume adjoined to mucosa 
3 Gy/fraction was delivered, and 4 Gy/fraction in other patients. Average administered total 
dose was 34 Gy (range 18–48 Gy), average implant volume 85 cm3 (range 34–265 cm3). Dose 
distribution was evaluated according to dose‐volumes histogram (DVH), also ensuring that 
implant volume irradiated by 200% of the prescribed dose (V200) would not exceed 10% PTV. 
The 1‐year and 2‐year overall survival was 56% and 37%, respectively, local control was 69% 
and 67%, respectively, progression‐free survival was 54% and 45%, respectively. Medium 
grade mucositis was diagnosed in most patients; late reactions (grade 3 and 4) were diag-
nosed in five (16%) patients: two were diagnosed with soft tissue necrosis, one had esophago‐
cutaneous fistula, one had lower jaw bone necrosis and one patient was diagnosed with 
tongue atrophy and fibrosis along with speech disorder. No grade 5 complications occurred. 
Tselis et al. used the accelerated hypofractionated 192Ir‐HDR‐BRT to treat 74 diagnosed with 
isolated head and neck cancer relapse in neck [7]. Patients had previously received radiation 
therapy or chemoradiation therapy; administered median total dose was 60 Gy (range 
22–72 Gy). Due to primary tumor, surgery was performed on 43 (58%) patients; lymphade-
nectomy was performed at the same time on 33 of these patients (45%). Median time interval 
after primary treatment until isolated relapse was 12 months (range 3–207 months). Median 
target volume was 64.7 cm3 (range 6.4–622 cm3). Prior to HDR‐BRT, 9 (12%) patients have been 
treated using external beam radiation therapy, administered median dose 40 Gy (range 
20–70 Gy); 48 (65%) patients received chemotherapy; five (8%) received surgical treatment. 
Median time interval between external beam reirradiation therapy, last palliative chemother-
apy course, or surgery and the beginning of HDR‐BRT was 221 days (range 68–476 days), 53 
days (range 22–819 days) and 149 days (range 94–251 days), respectively. A total of 12 (16%) 
patients were not additionally treated following primary treatment until procedures of HDR‐
BRT. During HDR‐BRT, median Karnofsky Performance Score was 80 (range 60–100). When 
performing HDR‐BRT, 71 (96%) patients were prescribed two daily fractions with minimum 
6‐hour separation interval, and median delivered single fraction dose was 3 Gy (range 2–5 Gy). 
For remaining three (4%) patients, the median delivered single fraction dose was 6 Gy (range 
6–10 Gy) delivered in one daily fraction. All patients were administered a median total dose 
of 30 Gy (range 10–36 Gy). A total of 69 (93%) patients were treated using stand‐alone HDR‐
BRT; five (7%) patients received this treatment in combination with external beam radiation 
therapy; median prescribed dose was 30.6 Gy (range 20–45 Gy). Dose distribution was evalu-
ated according to DVH with consideration of D90, and dose heterogeneity was assessed 
according to V100, V150 and V200. In 60 (81%) patients who were prescribed with single frac-
tion dose of 3 Gy, evaluated dosimetric parameters were as follows: D90 = 2.9 Gy (range 2.1–
3.7 Gy) = 96.7% of the administered dose. Resulting dosimetric parameters for all the patients: 
median D90—97.7% (range 70–123.3%); V100 = 88.8% (range 68.8–96.9%); V150 = 58% (range 
42–76%) and V200 = 38% (range 21–58%). Radiotherapy toxicity was evaluated according to 
RTOG/EORTC criteria. Median overall survival was 42 weeks; 1‐year, 2‐year and 3‐year over-
all survival reached 42%, 19% and 6%, respectively. The 1‐year local control was 67%, 2‐year—
67% and 3‐year—67%; 1‐year, 2‐year and 3‐year progression‐free survival was 42%, 37% and 
19%, respectively. After determining that the median target volume was ∼65 cm3, patients 
were divided into two groups, and it was found that in patients with target volume <65 cm3 
survival reached 13 months compared to 6 months in patients with target volume ≥65 cm3 
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(p = 0.0001). In patients who were prescribed with a treatment dose of <32.5 Gy based on cal-
culated EQD2, median survival was 9 months, while in patient group with accordingly calcu-
lated EQD2 ≥ 32.5 Gy median survival was 13 months (p = 0.098). In the scope of this study, no 
statistically significant difference has been found between patient survival and factors such as 
primary tumor location, histological type of tumor, T and N stages of the primary tumor. 
Also, no statistical significant difference has been determined between local control and pri-
mary tumor location, histological type of tumor, T and N stages of the primary tumor, tumor 
relapse volume, KPS or prescribed dose. Acute toxicity (grade 3 and 4) was diagnosed in 5% 
of patients; frequency of late complications (grade 3 and 4) reached 8%, including three diag-
nosed with fistula. No grade 5 complications were diagnosed. Narayana et al. used HDR‐BRT 
to treat 30 patients diagnosed with recurrent head and neck cancer [32]. About 77% of all 
patients had been diagnosed with local or regional relapse in previously irradiated location. 
Prior to HDR‐BRT, 18 patients received surgical treatment, and they were prescribed with a 
total dose of 34 Gy administered in two 3.4 Gy daily fractions. A total of nine patients were 
treated using stand‐alone HDR‐BRT; a total dose prescribed was 40 Gy in two 4 Gy daily frac-
tions. Remaining three patients received external beam radiation therapy 40–50 Gy and HDR‐
BRT 20 Gy, delivering two 4 Gy daily fractions. Toxicity was evaluated according to RTOG 
and NCI‐CTC Version 3 toxicity criteria. The 2‐year overall survival and local control were 
63% and 71%, respectively. In group of patients who received surgical treatment and HDR‐
BRT, 2‐year local control was better compared to remaining patients (88% vs. 40%, p = 0.05), 
although no statistically significant difference has been found when comparing the overall 
survival in these groups (70% vs. 43%, p = 0.66). Early complications (grade 3 and 4) were 
diagnosed in four patients; late grade 2 toxicity was diagnosed in six (20%) patients, late grade 
3 toxicity was diagnosed in four (13%) patients: soft tissue fibrosis in two cases, one patient 
was diagnosed with trismus and one patient was diagnosed with a strong constant pain 
requiring nerve blockade to suppress it. No toxic reactions grade 4 and 5 occurred. Pellizzon 
et al. published results from a retrospective study which involved 21 patients diagnosed with 
head and neck cancer relapse in neck lymph nodes [33]. A total of 15 patients (71.4%) previ-
ously had been treated using external beam radiation therapy, with median total adminis-
tered dose of 52 Gy (range 30–66 Gy). Median time between initial and repeated treatments 
was 32 months (range 14–86 months). All patients received surgical treatment; median time 
between surgery and HDR‐BRT was 5 days (range 4–12 days). 192Ir‐HDR‐BRT treatment 
planning and optimization has been carried out in accordance with the Paris System princi-
ples, ensuring that the “hot spots” in the quarter of PTV would not exceed 135% of prescribed 
dose, and the skin‐affecting dose would not exceed 60% of prescribed dose. Median pre-
scribed total dose was 35 Gy (range 12–48 Gy), number of fractions 3–16 (median—8 frac-
tions). After HDR‐BRT, patients underwent external beam radiation therapy; median time 
between these treatment stages was seven days (range 1–37 days). Median prescribed total 
dose was 45 Gy (range 30–66 Gy), and in patients who already had been treated using external 
beam radiation therapy median dose was 30 Gy (range 25–50 Gy). The 5‐year and 8‐year over-
all survival was 50% and 42.9%, respectively, disease free survival was 42.5% and 28.6%, 
respectively. During this study, only a single factor has been determined which influences 
overall survival and progression‐free survival in statistically meaningful way (p = 0.0002 and 
Radiotherapy112
p = 0.0007, respectively), and this prognostic factor is the condition of resection margin 
( positive vs. negative resection margin). About four (19.4%) patients were diagnosed with 
early radiation reactions, and four patients had severe late complications: three were diag-
nosed with local non‐healing wounds, one patient had wide‐neck tissue fibrosis. There were 
no cases of soft‐tissue necrosis. Schiefke et al. treated 18 patients diagnosed with locally 
advanced head and neck cancer; treatment was carried out by performing tumor resection 
and delivering 192Ir‐HDR‐BRT [34]. A total of 5 patients were treated for primary head and 
neck cancer; 13 patients were treated for relapse. Out of 13, 10 patients who were diagnosed 
with cancer recurrence had radical tumor resection during initial treatment, eight of them had 
lymphadenectomy performed simultaneously; following surgery, external beam radiation 
therapy was administered with a total prescribed dose 59.4–69.9 Gy; one patient received 
adjuvant chemotherapy. All the patients included in this study received surgery by perform-
ing partial tumor resection and implantation of brachytherapy catheters, ensuring that the 
post‐operative bed including 5 mm margin is covered by 100% isodose. Median time between 
surgery and HDR‐BRT was 6 days (range 4–41 days), median total dose was 30 Gy (range 
15–44.8 Gy), with median prescribed single fraction dose of 3 Gy (1.5–3.5 Gy); two daily frac-
tions were prescribed with minimal interval of 8 hours. Median PTV volume was 103.1 cm3 
(range 25.4–220 cm3). A total of eight patients additionally received external beam radiation 
therapy, total dose 6–49.6 Gy (median 45 Gy); 7 patients received chemotherapy. In patients 
treated for relapse, median survival was 22.8 months (range 2.4–43.8 months) and 2‐year 
overall survival and progression‐free survival was 59.8 and 64.8%, respectively. Median pro-
gression‐free survival was 12.8 months (range 4–27 months). Severe late toxicity was diag-
nosed in four (22.2%) patients: one patient experienced bleeding from the carotid artery, one 
patient experienced abnormal healing of operating wounds and was diagnosed with fistula, 
two patients were diagnosed with osteonecrosis.
In published studies involving application of HDR‐BRT to treat head and neck cancer relapse, 
3 Gy fractions to total dose of 30 Gy, or 4 Gy fractions to total dose of 40 Gy have been deliv-
ered. Using these treatment regimens, 2‐year overall survival was 19–63%, local control was 
67–71%, progression‐free survival was 37–64.8%, and the frequency of late grade 3 and 4 
toxicity was 8–22.2%. No grade 5 reactions were diagnosed (Table 2).
Application of HDR‐BRT is limited by technical possibilities to implant brachytherapy cath-
eters, and therefore this method of therapy is suitable to treat lip, oral cavity, oropharyngeal 
cancers, and also is suitable for inoperable recurrent cervical lymphadenopathy.
Recommendations for HDR‐BRT (Figure 3):
1. High‐dose‐rate brachytherapy is effective and safe method of treatment, which can be 
applied to treat local head and neck cancer relapse diagnosed in previously irradiated 
area, delivering total dose of 30–40 Gy in 3–4 Gy/fraction, in two daily fractions separated 
by minimum 6‐hour interval.
2. High‐dose‐rate brachytherapy is recommended to treat head and neck cancer relapse if 
the relapse volume does not exceed 30–40 cm3.
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3. In order to avoid severe late radiotherapy complications and to ensure local control, it 
is recommended that: PTV volume is ≥5 mm away from bone structures; PTV volume 
 irradiated by 200% of prescribed dose (V200) does not exceed 10% of total PTV; skin‐
affecting dose does not exceed 60% of prescribed dose; homogeneity index (HI) is no less 
than 0.6–0.7; dose non‐uniformity ratio (DNR) is not higher than 0.25–0.35.
2.3. Reirradiation with proton beam therapy
External beam radiation therapy extends survival in patients diagnosed with head and neck 
cancer; however, occurring xerostomia, dysphagia, impaired ability to sense taste, post‐
radiation caries worsens the quality of life [35]. It is likely that delivering repeated exter-
nal beam radiation therapy in patients diagnosed with head and neck cancer relapse would 
lead to higher frequency of late reactions. Because of advantages associated with dosimet-
ric parameters of proton therapy compared with IMRT and F‐SBRT, this therapy is used for 
reirradiation treatment with aim to reduce treatment‐related toxicity and to protect previ-
ously irradiated healthy tissues. So far only several studies have been published involving 
Author N Treatment Late toxicity grade 3‐4 Results
Hepel et al. [31] 22 192Ir‐HDR‐BRT median dose 34 Gy 
(18–48 Gy)/3–4 Gy/fx
16% 1 y OS—56%
2 y OS—37%
1 y DFS—54%
2 y DFS—45%
Narayana et al. [32] 39 (a) Surgery + 192Ir‐HDR‐BRT 34 Gy/(n = 18)
(b) 192Ir‐HDR‐BRT 40 Gy/(n = 9)
(c) RT 40–50 Gy + 192Ir‐HDR‐BRT 20 Gy/(n = 3)
13%
No grade 4 toxicity
2 y OS—63%
2 y LC—71%
Tselis et al. [7] 100 (a) 192Ir‐HDR‐BRT, median dose 30 Gy 
(30–36 Gy)/(n = 69)
(b) 192Ir‐HDR‐BRT+RT, median dose 30.6 Gy 
(20–45 Gy)/(n = 5)
8% 1 y OS—42%
2 y OS—19%
3 y OS—65%
1 y LC—67%
2 y LC—67%
3 y LC—67%
1 y DFS—42%
2 y DFS—37%
3 y DFS—19%
Pellizzon et al. [33] 84 (a) Surgery + 192Ir‐HDR‐BRT, median dose 
35 Gy (12–48 Gy)/3–4 Gy/fx + RT, median dose 
45 Gy (30–60 Gy)/(n = 6)
(b) Surgery + 192Ir‐HDR‐BRT median dose 
35 Gy (12–48 Gy)/3–4 Gy/fx + RT, median dose 
30 Gy (25–50 Gy)/(n = 15)
19.4% 5 y OS—50%
8 y OS—42.9%
5 y DFS—42.5%
8 y DFS—28.6%
Schiefke et al. [34] 23 (a) Surgery+192Ir‐HDR‐BRT, median dose 
30 Gy (15–44.8 Gy)/(n = 10)
(b) Surgery+192Ir‐HDR‐BRT, median dose 
30 Gy (15–44.8 Gy)+RT, median dose 45 Gy 
(6–49.6 Gy)/(n = 8)
22.2% 2 y OS—59.8%
2 y DFS—64.8%
Notes: 192Ir, iridium 192; HDR‐BRT, high dose rate brachytherapy; RT, external beam radiotherapy; OS, overall survival; 
DFS, disease free survival; LC, local control.
Table 2. Summary of published data on interstitial high‐dose‐rate brachytherapy for head and neck cancer relapses.
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 application of  proton beam therapy to treat head and neck cancer relapse. Romesser et al. 
published results of a multi‐institutional study during which 92 patients were treated using 
proton beam therapy [36]. Median follow‐up was 13.3 months (range 8.2–19.2 months) for 
surviving patients, and 10.4 months for all patients (range 5.3–17.5 months). In total, 65 
(70.7%) men and 27 (29.3%) women were included in this study with a median age of 63 years 
(range 51.5–70 years); 70.7% of patients had Karnofsky Performance Score 80 and higher. 
Median time between initial radiotherapy and proton beam therapy was 34.4 months (range 
8.2–19.2 months). Study subject group was very heterogeneous according to tumor localiza-
tion: oropharynx—17 (18.5%), nasal cavity and paranasal sinuses—12 (13%), larynx or hypo-
pharynx—10 (10.9%), salivary glands—11 (12%) and nasopharynx—9 (9.8%); also, there were 
included five patients with skin, eight patients with skull base tumors and eight patients 
diagnosed with tumors in other locations. Most of subjects—52 (56.5%)—had histologically 
confirmed diagnosis of squamous cell carcinoma. Prior to proton beam therapy, 36 (39.1%) 
patients received surgical treatment; median prescribed dose was 60.6 Gy (range 50–66.1 Gy). 
About 44 (47.8%) patients received concurrent biological therapy based on cetuximab. The 
12‐month regional control was 25.1%; skull base was the most frequent location of local recur-
rence. The 12‐month overall survival reached 65.2%, freedom‐from‐distant metastasis was 
84%. Late grade 3 and higher toxic skin reactions and dysphagia were diagnosed in six (8.7%) 
Figure 3. HDR‐BRT dosimetric plan shown on axial (A), coronal (B) and sagittal (C) CT slice, 3D view of PTV (red) (D) 
for a patient with isolated neck recurrence of tonsil squamous cell carcinoma. PTV volume was 37.85 cm3, V100 = 85.89%, 
V150 = 32.28%, V200 = 12.1%, HI = 0.62, DNR = 0.37.
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and four (7.1%) patients, respectively, two (2.9%) patients were diagnosed with treatment‐
related bleeding (grade 5 toxicity). Phan et al. used proton beam therapy to treat 60 patients, 
including 55 diagnosed with head and neck cancer relapse and five diagnosed with second-
ary tumor [37]. Largest segment (16 patients) consisted of recurrent oropharyngeal tumors, 
five nasopharyngeal tumors, 11 sinonasal tumors, eight parotid gland tumors. A total of 40 
(66.7%) patients had histologically confirmed squamous cell carcinoma; median time between 
initial radiation therapy and proton beam therapy was 47.1 months (range 7.3–438.2 months), 
median follow‐up was 13.6 months (range 0–50 months). A total of 35 (58%) patients received 
surgical treatment, 44 (73%) received proton beam therapy in combination with chemother-
apy. Median prescribed dose of adjuvant proton beam therapy was 61.5 Gy (range 50–70 Gy); 
in patients who received a definitive PBRT median dose was 66 Gy (range 50–70 Gy). The 
1‐year and 2‐year locoregional control was 68.4% and 55.9%, overall survival—81.3% and 
69%, progression‐free survival—60.1% and 48.2%, distant metastasis‐free survival—75% and 
63.7%, respectively. Frequency of late grade 3 toxicity was 20% (12 patients); no grade 4 toxic-
ity was diagnosed, yet death of two (3%) patients was potentially treatment related.
PBRT is an effective treatment method for patients diagnosed with head and neck cancer 
relapse; however, results of this treatment method are difficult to compare with other radio-
therapy regiments (Table 3). Study groups were highly heterogeneous according to the pri-
mary tumor location, different cancer types have been included (squamous cell carcinoma, 
sarcoma, adenocarcinoma, etc.), part of patients received surgical treatment before proton 
beam therapy, others received combined chemotherapy or biological therapy. It is therefore 
necessary to conduct further studies with aim to assess advantages of proton beam therapy 
compared with IMRT or F‐SBRT.
Recommendations for PBRT:
1. Proton beam therapy is recommended for patients with good functional status, decid-
ing individually and comparing treatment planning dosimetric parameters of PBRT and 
IMRT or F‐SBRT to each other.
2. Proton beam therapy is recommended for patients if relapse volume does not exceed 
50 cm3.
Author N Treatment Late toxicity grade 3–4 Results
Romesser et al. [36] 92 (a) Surgery+PBRT (n = 36)
(b) Biological therapy+PBRT (n = 44)
Median dose 60.6 Gy (50–66.1 Gy)
Dysphagia—7.1%, skin 
reactions—8.7%
grade 5—2.9%
1 y OS—65.2%
1 y DFS—84%
Phan et al. [37] 60 (a) Surgery+PBRT/(n = 35)
(b) PBRT+CHT/(n = 44)
Median dose 61.5 Gy (50–70 Gy)
20%
Grade 5—2.8%
1 y OS—81.3%
2 y OS—69%
1 y LC—68.4%
2 y LC—55.9%
1 y DFS—75%
2 y DFS—63.7%
Notes: PBRT, proton beam therapy; CHT, chemotherapy; OS, overall survival; DFS, disease free survival; LC, local 
control.
Table 3. Summary of published data on PBRT for recurrent head and neck cancer.
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2.4. Organs at risk
2.4.1. Spinal cord and brain stem
In some studies, the cumulative dose limit was ≤60 Gy, delivered in 2 Gy/fraction, 5 days/
week (biologically equivalent dose [BED] 120 Gy
2
). There were no cases of myelopathy in 
these studies, and a minimal time interval between primary therapy and reirradiation was 6 
months [27, 38, 39]. When applying fractionation regimen of 2 Gy/day, and after irradiating 
the full cord cross‐section to a total dose of 50, 60 and ∼69 Gy, the frequency of myelopathy 
was 0.2%, 6% and 50%, respectively [39]. However, most authors recommend not to exceed 
the cumulative dose of 50 Gy [19, 24, 26]. When using the hypofractionated stereotactic body 
radiation therapy, it is recommended not to exceed the cumulative dose of 25 Gy (2 Gy—
equivalent dose, α/β = 2), when the total dose of primary radiotherapy does not exceed 50 Gy 
and the minimal time between two radiotherapy courses is 5 months [40].
2.4.2. Mandible
Up to this date there are no clear volume and dose limitations when using the reirradia-
tion therapy, although osteoradionecrosis is one of the possible late toxic reactions. Studies 
published by De Crevoisier et al. and Duprez et al. indicate osteoradionecrosis frequencies 
of 8% and 3.6%, when administering total cumulative dose of 130 Gy, using conventional 
radiotherapy [10, 26]. In a research conducted by Salama et al., the total cumulative dose was 
135 Gy, and frequency of osteoradionecrosis was 11% [41]. When using repeated stereotactic 
body radiation therapy in patients who received a total dose of 66–70.2 Gy during the primary 
radiotherapy, it is recommended not to exceed 25–40 Gy/5 fractions (BED 40–90 Gy
2
) [40].
2.4.3. Larynx/hypopharynx
In study conducted by Tanvetyanon et al., frequency of laryngeal toxicities of grade 3 and 
higher was 7.8%, when administering a total cumulative dose of 124 Gy [21]. Takiar et al. com-
pleted a 15‐year analysis and published its results, which include: chondroradionecrosis after 
delivering 140 Gy total cumulative dose; non‐healing ulcer and stenosis requiring surgery 
after ≥120 Gy [42]. It is therefore recommended that the total cumulative dose for larynx and 
hypopharynx does not exceed 120 Gy.
It is recommended to reduce (according to possibilities) the total dose which involves such 
organs as base of tongue, carotid arteries, jugular veins, oral cavity, sternocleidomastoid mus-
cle, parotid and submandibular glands; however, there is no dose limit established for these 
body structures.
3. Conclusions
Reirradiation therapy is suitable and safe method of treatment for patients diagnosed with 
head and neck cancer relapse. It is important to take into consideration the functional status 
of the patient, recurrence location and volume, and time interval between initial radiotherapy 
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and reirradiation. Surgical treatment, chemotherapy or biological therapies are more efficient 
methods of treatment when combined with reirradiation. Currently there is a lack of random-
ized clinical trials comparing effectiveness and toxicity of different radiotherapy methods, so 
for each case the potential of reirradiation therapy must be evaluated individually, consider-
ing recommendations presented here.
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